Mark Leiser is the Editorial Director for Healio, a platform that provides healthcare professionals with news, information, and education. With a focus on medical advancements and breakthroughs, Mark's articles cover a wide range of topics including cancer therapies, clinical trials, and emerging treatments.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Mark's coverage indicates a strong focus on healthcare and pharmaceuticals, particularly in the context of clinical trial data and scientific breakthroughs. He is most likely to be interested in pitches that provide access to exclusive data or insights related to new treatments for cancer, hemophilia, gene therapy, or other significant medical advancements.
Given Mark’s reliance on citing data, he may respond well to expert sources who can offer detailed analysis of clinical trial results or scientific developments in the mentioned fields. Pitches should emphasize the depth of expertise and ability to provide unique perspectives based on robust evidence.
It is important for potential contributors reaching out to Mark Leiser with relevant information regarding recent discoveries or groundbreaking research within these specialized areas.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Mindy Valcarcel, Mark Leiser
The addition of retifanlimab to standard first-line chemotherapy improved outcomes for certain patients with advanced squamous cell carcinoma of the anal canal, according to randomized phase 3 study results presented at ESMO Congress.
By: Mindy Valcarcel, Mark Leiser
The addition of lenvatinib and pembrolizumab to transarterial chemoembolization extended PFS for patients with intermediate-stage hepatocellular carcinoma, according to randomized phase 3 study results.
By: Mark Leiser, Mindy Valcarcel
The addition of six cycles of radium-223 to first-line enzalutamide extended radiographic PFS for men with metastatic castration-resistant prostate cancer, according to results of a randomized phase 3 trial.
By: Mark Leiser, Mindy Valcarcel
Use of pembrolizumab with neoadjuvant chemotherapy and as monotherapy in the adjuvant setting extended OS for patients with early-stage triple-negative breast cancer, according to results from the randomized phase 3 KEYNOTE-522 trial.
By: Mindy Valcarcel, Mark Leiser
Use of durvalumab before and after radical cystectomy improved outcomes for patients with muscle-invasive bladder cancer, according to results of the randomized phase 3 NIAGARA trial.
PROVIDENCE, Rhode Island — Physicians and other health care professionals can utilize social media to support diversity, equity and inclusion in cancer care, according to a presenter at the COSMO Meeting.
PROVIDENCE, Rhode Island — Misinformation about cancer is prevalent on social media, spanning across platforms and malignancy types, according to a presenter at the COSMO Meeting.
By: Mark Leiser
PROVIDENCE, Rhode Island — The influence digital opinion leaders have on health care stakeholders and patients will continue to grow as new
ASH has announced its three inaugural quality improvement champions.The initiative recognizes clinicians who implemented intervention-based projects designed to improve care quality by addressing underuse or overuse of procedures or tests, as well as the implementation of guideline recommendations to ensure safety and improve health care delivery.
By: Mark Leiser, Jennifer Byrne
A high percentage of childhood survivors do not undergo guideline-recommended monitoring for late effects, according to results of a population-based study.
(833) 317-6278 
